Literature DB >> 3186330

Acute hemodynamic effects of nifedipine in infants with bronchopulmonary dysplasia and pulmonary hypertension.

J R Brownlee1, R H Beekman, A Rosenthal.   

Abstract

The acute hemodynamic effects of nifedipine were evaluated and compared to the effects of 95% oxygen in six children with bronchopulmonary dysplasia and pulmonary artery hypertension. The children ranged in age from 7-26 months and all were oxygen dependent. In the cardiac catheterization laboratory, hemodynamic data were collected in 95% oxygen, room air, and 15 and 30 min after nifedipine administration (0.5-0.6 mg/kg per nasogastric tube). Compared to values in room air, nifedipine resulted in a 34% decrease in pulmonary artery mean pressure (from 69.3 +/- 2.4 to 45.8 +/- 1.2 mm Hg, p = 0.03) and a 49% decrease in pulmonary vascular resistance (from 14.8 +/- 1.4 to 7.5 +/- 0.9 U/m2, p = 0.03). A linear relationship was found between the arterial pO2 and the change in the ratio of pulmonary to systemic resistance after nifedipine (% decrease in Rp/Rs ratio = 86.3 - 1.3 x pO2, r = -0.95, p = 0.004) suggesting that nifedipine may act to oppose the vascular effects of arterial hypoxemia. There was no significant change in heart rate, arterial pO2, or pCO2 with nifedipine, but cardiac output increased significantly. Compared to 95% oxygen, nifedipine achieved a lower pulmonary vascular resistance (7.5 +/- 0.9 versus 10.9 +/- 1.2 U/m2, p = 0.03) and a greater cardiac output (5.25 +/- 0.71 versus 3.54 +/- 0.35 liter/min/m2, p = 0.03) with comparable systemic oxygen delivery (699 +/- 85 ml versus 698 +/- 91 ml O2/min/m2, p = 1.0). Thus, nifedipine is an acute pulmonary vasodilator in some children with bronchopulmonary dysplasia.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3186330     DOI: 10.1203/00006450-198808000-00009

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  8 in total

Review 1.  Cor pulmonale in cystic fibrosis.

Authors:  M H Götz; O C Burghuber; U Salzer-Muhar; W Wolosczuk; M Weissel; E Hartter
Journal:  J R Soc Med       Date:  1989       Impact factor: 5.344

2.  Inhaled nitric oxide and oral nifedipine in a preterm infant with bronchopulmonary dysplasia and pulmonary hypertension.

Authors:  Enrico Rosati; Gianfranco Butera; Eduardo Bossone; Claudio De Felice; Giuseppe Latini
Journal:  Eur J Pediatr       Date:  2006-11-14       Impact factor: 3.183

3.  Upregulation of vascular calcium channels in neonatal piglets with hypoxia-induced pulmonary hypertension.

Authors:  Dinesh K Hirenallur-S; Steven T Haworth; Jeaninne T Leming; James Chang; Guillermo Hernandez; John B Gordon; Nancy J Rusch
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2008-09-05       Impact factor: 5.464

4.  Interdisciplinary Care of Children with Severe Bronchopulmonary Dysplasia.

Authors:  Steven H Abman; Joseph M Collaco; Edward G Shepherd; Martin Keszler; Milenka Cuevas-Guaman; Stephen E Welty; William E Truog; Sharon A McGrath-Morrow; Paul E Moore; Lawrence M Rhein; Haresh Kirpalani; Huayan Zhang; Linda L Gratny; Susan K Lynch; Jennifer Curtiss; Barbara S Stonestreet; Robin L McKinney; Kevin C Dysart; Jason Gien; Christopher D Baker; Pamela K Donohue; Eric Austin; Candice Fike; Leif D Nelin
Journal:  J Pediatr       Date:  2016-11-28       Impact factor: 4.406

5.  Effects of long-term sildenafil treatment for pulmonary hypertension in infants with chronic lung disease.

Authors:  Peter M Mourani; Marci K Sontag; D Dunbar Ivy; Steven H Abman
Journal:  J Pediatr       Date:  2008-10-31       Impact factor: 4.406

6.  Bronchopulmonary dysplasia in preterm infants: pathophysiology and management strategies.

Authors:  Carl T D'Angio; William M Maniscalco
Journal:  Paediatr Drugs       Date:  2004       Impact factor: 3.022

7.  Pulmonary artery pressure changes in the very low birthweight infant developing chronic lung disease.

Authors:  A B Gill; A M Weindling
Journal:  Arch Dis Child       Date:  1993-03       Impact factor: 3.791

8.  Plasma endothelin-1 like immunoreactivity levels in neonates.

Authors:  T Kojima; Y Isozaki-Fukuda; M Takedatsu; A Ono; Y Hirata; Y Kobayashi
Journal:  Eur J Pediatr       Date:  1992-12       Impact factor: 3.183

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.